An Ohio State study using objective lab tests of 60 adults finds long COVID often causes measurable smell, hearing, balance and cognitive problems, with age and severe illness linked to worse outcomes.

Salk's La Jolla team released a cloud-hosted atlas that charts how brain cells change with age. The open dataset aims to speed Alzheimer's and Parkinson's research.

Mid‑America Transplant has begun flying donor blood samples along a new Missouri drone corridor, trimming delivery time and costs while testing a Rolla hub. Partners say the route could improve access for rural hospitals.

Korsana will take Cyclerion’s Nasdaq listing through an all‑stock reverse merger backed by about $380M, giving the startup cash into 2029 and a faster route to 2027 readouts. The combined company will trade as KRSA.

A San Diego State survey finds wide AI use across CSU but deep disagreement over its effects; students and faculty want training, data protections and clearer governance.

A San Diego gene‑editing startup moved to Maryland Heights and plugged into St. Louis’s plant‑science network. Cheaper lab rent and a dense research ecosystem sped its restart.

The U.S. Army has conditionally selected Dugway Proving Ground and CyrusOne to enter exclusive talks on a roughly 1,200‑acre data center project to boost AI capacity; no lease is final.

Houston jeweler Johnny Dang says viral AI‑generated videos are falsely depicting him and his business. The clips spread fast — here’s what experts and new laws say.

Northwestern precision fMRI shows imagination taps higher-level association systems — default and language networks — rather than only replaying sensory cortex.

AT&T reached an agreement-in-principle with federal officials to invest up to $2 billion to upgrade FirstNet, aiming to expand coverage and lower program costs.

Seattle’s Rec Room will shutter on June 1, 2026 after saying costs outpaced revenue. Snap reportedly bought select assets while creators rush to export data.

SkyWater's Fab 25 purchase and a pending IonQ acquisition have lifted revenue and capacity, positioning Bloomington as a hub in the U.S. chip re‑shoring push. The deals mean more factory space, higher payrolls and a bigger role in quantum hardware supply chains.

Eli Lilly will buy Boston‑based Centessa for about $6.3B, adding an orexin agonist program led by cleminorexton. The deal pays $38 per ADS up front and could reach $47 with milestones.